Article Information
- Received November 7, 2012
- Revision received June 20, 2013
- Accepted July 25, 2013
- First published September 11, 2013.
- Version of record published September 11, 2013.
Author Information
- 1Centre de Recherche du CHU de Québec, CHUL-Neurosciences, Québec City, Québec G1V 4G2, Canada,
- 2Département de Psychiatrie et Neurosciences, Université Laval, Québec City, Québec G1K 7P4, Canada,
- 3Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada, and
- 4Department of Surgery (Neurosurgery), Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada
Author contributions
Author contributions: F.B. and R.M.B. designed research; F.B. performed research; F.B. and R.M.B. contributed unpublished reagents/analytic tools; F.B. and R.M.B. analyzed data; F.B. and R.M.B. wrote the paper.
Disclosures
- Received November 7, 2012.
- Revision received June 20, 2013.
- Accepted July 25, 2013.
This work was funded by the Canadian Institutes of Health Research (FRN 89820). We thank Drs. Larry Jordan, Tuan Bui, and Silvia Arber for their comments on the manuscript; Pratip Mitra, and Izabela Panek for helpful discussions; and Angelita Alcos, Bithika Ray, Nadia Farbstein, Stephen Whitefield, Damaso Sadi, Laura Baxter, Julian Green, and Meggie Reardon for technical support. We thank Drs. Gerald Zamponi and Terry Snutch for the anti-CaV3 antibodies; and Nathaniel Heintz, The Rockefeller University, Charles Gerfen, National Institutes of Health, and the Mutant Mouse Regional Resource Center for the Chx10::eGFP mice. F.B. was a Canadian Institutes of Health Research and Paralysis Project of America postdoctoral fellowship recipient.
- Correspondence should be addressed to Rob Brownstone, Departments of Surgery (Neurosurgery) and Medical Neuroscience, Dalhousie University, P.O. Box 15000, Halifax, Nova Scotia, Canada B3H 4R2. Rob.Brownstone{at}dal.ca
Online Impact